NICE positive recommendation for Opdivo + Yervoy to treat malignant pleural mesothelioma
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM), in England and Wales
This treatment combination is the first immunotherapy in over ten years to be made available via the NHS for the treatment of untreated, unresectable MPM.
MPM is a type of mesothelioma caused primarily by exposure to asbestos. It affects the chest and lungs and is often diagnosed late, giving patients an average of less than a year’s survival without treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins